Scarica l'app Stockscreener
27.12
2.77%
0.73
Dopo l'orario di chiusura:
27.15
0.03
+0.11%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché TGTX Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$26.39
Aprire:
$26.44
Volume 24 ore:
2.27M
Relative Volume:
1.11
Capitalizzazione di mercato:
$4.31B
Reddito:
$264.79M
Utile/perdita netta:
$-14.36M
Rapporto P/E:
-246.55
EPS:
-0.11
Flusso di cassa netto:
$-28.11M
1 W Prestazione:
-4.51%
1M Prestazione:
-26.87%
6M Prestazione:
-12.23%
1 anno Prestazione:
+31.33%
Intervallo 1D:
$26.05
$27.12
Intervallo di 1 settimana:
$25.28
$28.88
Portata 52W:
$20.39
$46.48
Tg Therapeutics Inc Stock (TGTX) Company Profile
Nome
Tg Therapeutics Inc
Settore
Industria
Telefono
(212) 554-4484
Indirizzo
2 GANSEVOORT STREET, 9TH FLOOR, NEW YORK, NY
Confronta TGTX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
TGTX
Tg Therapeutics Inc
|
27.12 | 4.19B | 264.79M | -14.36M | -28.11M | -0.11 |
|
VRTX
Vertex Pharmaceuticals Inc
|
387.77 | 96.01B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
556.55 | 57.86B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
429.93 | 57.02B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
637.56 | 39.10B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.10 | 34.45B | 3.81B | -644.79M | -669.77M | -6.24 |
Tg Therapeutics Inc Stock (TGTX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-10 | Ripresa | Goldman | Neutral |
| 2024-10-29 | Iniziato | TD Cowen | Buy |
| 2023-08-02 | Aggiornamento | Goldman | Sell → Neutral |
| 2023-06-26 | Ripresa | Jefferies | Buy |
| 2022-05-20 | Iniziato | BofA Securities | Underperform |
| 2022-02-23 | Reiterato | B. Riley Securities | Buy |
| 2021-11-15 | Downgrade | Goldman | Neutral → Sell |
| 2021-04-20 | Iniziato | Goldman | Neutral |
| 2021-04-19 | Reiterato | H.C. Wainwright | Buy |
| 2020-09-01 | Iniziato | JP Morgan | Overweight |
| 2020-08-11 | Reiterato | H.C. Wainwright | Buy |
| 2020-06-05 | Iniziato | Evercore ISI | Outperform |
| 2020-01-17 | Reiterato | H.C. Wainwright | Buy |
| 2019-11-27 | Ripresa | B. Riley FBR | Buy |
| 2019-02-06 | Ripresa | Jefferies | Buy |
| 2018-09-25 | Downgrade | Raymond James | Strong Buy → Outperform |
| 2018-03-09 | Reiterato | B. Riley FBR, Inc. | Buy |
| 2017-12-01 | Ripresa | B. Riley FBR, Inc. | Buy |
| 2017-11-14 | Ripresa | H.C. Wainwright | Buy |
| 2017-04-25 | Iniziato | Jefferies | Buy |
| 2017-03-06 | Reiterato | FBR & Co. | Outperform |
| 2016-10-06 | Ripresa | Brean Capital | Buy |
| 2016-05-27 | Iniziato | SunTrust | Buy |
| 2015-12-01 | Iniziato | FBR Capital | Outperform |
| 2015-09-09 | Iniziato | Raymond James | Strong Buy |
| 2015-08-12 | Ripresa | H.C. Wainwright | Buy |
| 2015-06-19 | Reiterato | Brean Capital | Buy |
| 2014-12-11 | Reiterato | ROTH Capital | Buy |
| 2014-12-10 | Reiterato | ROTH Capital | Buy |
Mostra tutto
Tg Therapeutics Inc Borsa (TGTX) Ultime notizie
SHAREHOLDER ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against TG Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm - ACCESS Newswire
TG Therapeutics Faces Regulatory and Legal Challenges Amid AI Risks - AInvest
Navigating AI Risks: TG Therapeutics Faces Regulatory and Legal Challenges - The Globe and Mail
TG Therapeutics Faces Regulatory and Legal Risks with AI Integration - AInvest
TG Therapeutics Boosts Financial Strength with New Securities Filing - AInvest
TG Therapeutics Inc's Financial Performance and Strategic Positioning - AInvest
Willdan Group's Price Target Raised by Wedbush to $120, Up 41.18% - AInvest
Tg Therapeutics 2025 Q2 Earnings Net Income Surges 309.8% - AInvest
TG Therapeutics: Strategic Capital Flexibility Fuels Briumvi's Global Expansion and R&D Momentum - AInvest
TG THERAPEUTICS, INC. SEC 10-Q Report - TradingView
TG Therapeutics raises BRIUMVI 2025 revenue guidance to $575M while advancing subcutaneous pipeline - MSN
TG Therapeutics (TGTX) Slashes 18% on Lower 2025 Sales Guidance - MSN
TG Therapeutics falls after Q2 miss despite guidance raise - MSN
TGTX Down as Q2 Earnings Miss Mark, Briumvi Sales Drive Top Line - MSN
TG Therapeutics, Inc. (NASDAQ:TGTX) Q2 2025 Earnings Call Transcript - Insider Monkey
TR | OpenAI4o Maintains TG Therapeutics(TGTX.US) With Hold Rating, Cuts Target Price to $30 - 富途牛牛
TGTX Stock Falls 14.1% Amid Market Volatility - AInvest
TGTX Raises FY25 Revenue Projection, BRIUMVI Target Increased - AInvest
TG Therapeutics’ Earnings Call Highlights BRIUMVI Success - TipRanks
Tg Therapeutics shares fall 1.06% after-hours as clinical trial updates and legal risks weigh on sentiment. - AInvest
TGTX Down As Q2 Earnings Miss Mark, Briumvi Sales Drive Top Line - Barchart.com
New Lantern Expands AI Radiology Platform with Mammography and PET/CT Viewers - AInvest
TG Therapeutics (TGTX) Misses Q2 Earnings Estimates - MSN
TG Therapeutics Second Quarter 2025 Earnings: Misses Expectations - simplywall.st
TG Therapeutics Q2 2025 Earnings Call Transcript - MarketBeat
TG Therapeutics Inc (TGTX) Q2 2025 Earnings Call Highlights: Robust Revenue Growth and ... - Yahoo Finance
TG Therapeutics Inc (TGTX) Q2 2025 Earnings Call Highlights: Robust Revenue Growth and ... By GuruFocus - Investing.com Canada
TG Therapeutics Inc (TGTX) Q2 2025 Earnings Call Highlights: Rob - GuruFocus
TG Therapeutics: Q2 Earnings Snapshot - Connecticut Post
TG Therapeutics Boosts Revenue Forecast Amid Strong BRIUMVI Sales - TipRanks
TG Therapeutics Stock Plunges 17.99% on Missed Earnings Despite Strong Revenue Surging Trading Volume Ranks 325th in Market Activity - AInvest
Update: TG Therapeutics Shares Fall After Q2 Earnings Miss Expectations - 富途牛牛
Investor Calendar Invites You to the TG Therapeutics, Inc First Quarter 2016 Earnings Conference Call and Webcast Live on Tuesday May 10, 2016 - ACCESS Newswire
Why Top 3% Stock TG Therapeutics Crashed Despite Raising Its 2025 Outlook - Investor's Business Daily
Health Care Stocks See Gains On Strong Results And Approvals - Finimize
TG Therapeutics stock falls despite in-line Briumvi sales as BofA reiterates Underperform - Investing.com India
TG Therapeutics Stock Tumbles 15% After Disappointing Q2, But Company Reaffirms Confidence In Multiple Sclerosis Drug - Stocktwits
Crude Oil Falls 1.5%; ON Semiconductor Shares Plunge After Q2 Results - Benzinga
TG Therapeutics Stock Tumbles 16% After Disappointing Q2, But Company Reaffirms Confidence In Multiple Sclerosis Drug - MSN
Why Is TG Therapeutics Stock Falling Monday?TG Therapeutics (NASDAQ:TGTX) - Benzinga
TG Therapeutics Q2 Revenue Up 91% - The Motley Fool
TG Therapeutics Q2 Revenue Up 91% - Nasdaq
TG Therapeutics: Strong Market Position and Growth Prospects Make It an Attractive Buy - TipRanks
TG Therapeutics Q2 2025: Unpacking Contradictions in Market Share, Subcutaneous Trials, and Payer Demand Trends - AInvest
TG Therapeutics Plunges 15.76%—Is the Earnings Miss Just the Beginning? - AInvest
TG Therapeutics and BRIUMVI: A Deep Dive into Accelerating Revenue and Strategic Expansion in the MS Market - AInvest
Earnings call transcript: TG Therapeutics Q2 2025 misses EPS, raises revenue - Investing.com UK
TG Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
TG Therapeutics Raises Outlook As BRIUMVI Sales Climb - Finimize
TG Therapeutics Reports Q2 Profit, Misses Wall Street ExpectationsNews and Statistics - IndexBox
Tg Therapeutics Inc Azioni (TGTX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.91%
3.06%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):